Almirall and IRB Barcelona research for skin disease therapeutics discovery

pharmafile | January 18, 2022 | News story | Manufacturing and Production  

Almirall and IRB Barcelona (the Institute for Research in Biomedicine) have announced a research collaboration to identify the new oral treatments for immune-inflammatory skin diseases with remaining high unmet medical needs.

The collaboration aims to meet these needs using a novel therapeutic modality, called molecular glue degraders. These could represent an opportunity to expand the scope of druggable targets with small, drug-like molecules, that can reprogram natural cellular mechanisms to selectively remove disease driving proteins from human tissues.

Almirall scientists have identified several proteins whose abnormal function is associated with inflammatory immune skin diseases. However, many of these potentially therapeutically relevant proteins are not amenable to conventional small-molecule inhibitors, as they lack defined ligand-binding pockets. Ligand binding pockets are the cavities on the surface or inside of a protein, that has suitable properties for binding.

Molecular glue degraders can harness and reprogram natural cellular mechanisms, to selectively remove disease driving proteins from human tissues. They achieve this by “gluing” between these relevant proteins, and the machinery used by cells to naturally tag and destroy proteins. These monovalent degraders therefore offer a new avenue to induce the degradation of potentially disease-causing proteins, which cannot be targeted with conventional therapeutic agents.

“We are very excited about this collaboration with Almirall. It’s an amazing opportunity to put their knowledge and experience in dermatology, together with our expertise in molecular glues to accelerate drug discovery to treat skin diseases,” commented Cristina Mayor-Ruiz, PhD, Junior Group Leader at IRB Barcelona. “The biochemical characteristics of molecular glues make them suitable candidates, and this innovative approach could really mark a turning point in dermatological pharmacology. So much looking forward to making this vision a reality together with Almirall´s fantastic team.”

Ana Ovey

Related Content

No items found

Latest content